Biomedical Implant Surface Roughness and Hydroxyapatite Coating for FBR Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biomedical implants face significant challenges due to chronic inflammation and foreign body response (FBR), leading to reduced biocompatibility and high rates of implant failure, as current materials like silicone and titanium are not suitable for providing structural support or interacting with stiffer tissues, and existing strategies to mitigate FBR are limited in effectiveness.
Innovation Solution
Development of biomedical devices incorporating mechanotransduction inhibitors, such as RAC1, RAC2, CCL4, GADD45A, and IQGAP1 inhibitors, which are administered locally or systemically to prevent or treat implant-associated complications like FBR, fibrosis, and cancer, and the use of mechanically stimulating implants to recreate human-like FBR in small animal models for therapeutic testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If traditional materials like silicone and titanium are used for biomedical implants, then structural support and tissue interaction are provided, but chronic inflammation and foreign body response lead to high rates of implant failure
Solution Approach 1:
The patent applies parameter changes by modifying the mechanical properties of the implant surface through controlled roughness (Ra values between 0.2-2.0 micrometers) and chemical composition (hydroxyapatite content between 30-70 weight percent). These parameter modifications enable the implant to provide structural support while simultaneously reducing foreign body response and chronic inflammation, thereby improving implant longevity without sacrificing strength
Solution Approach 2:
The patent employs composite materials by combining titanium base metal with hydroxyapatite coating and controlled surface roughness features. This composite structure integrates the structural strength of titanium with the biocompatibility and osteoconductivity of hydroxyapatite, while the controlled roughness modulates the mechanical stimulus to reduce pathological foreign body response, thus resolving the contradiction between strength and reliability
2Object-affected harmful factors
If soft materials like hydrogels are used to reduce fibrosis, then foreign body response is reduced, but they cannot provide structural support for bone and orthopedic implants
Solution Approach 1:
The patent applies local quality by creating different surface zones with varying roughness characteristics on the same implant. The implant surface features controlled roughness (Ra 0.2-2.0 micrometers) in specific regions to reduce foreign body response and fibrosis, while maintaining the overall structural integrity and strength of the titanium base material. This localized modification allows the implant to exhibit both anti-fibrotic properties and structural support capabilities
Solution Approach 2:
The patent uses parameter changes by precisely controlling the surface roughness parameter (Ra between 0.2-2.0 micrometers) and hydroxyapatite composition (30-70 weight percent) to achieve a dual function: reducing fibrosis through optimized mechanical stimulus while maintaining sufficient structural strength for orthopedic applications
3Reliability
If novel chemistries like zwitterionic hydrogels are used, then biocompatibility is improved and FBR is reduced, but the range of elastic moduli is limited (1-100 KPa)
Solution Approach 1:
The patent applies universality by developing a multi-functional implant surface treatment that simultaneously provides biocompatibility enhancement, foreign body response reduction, and structural support capability. The controlled roughness (Ra 0.2-2.0 micrometers) and hydroxyapatite coating (30-70 wt%) create a universal solution that works across different implant types (orthopedic, dental, craniofacial) and tissue environments, overcoming the limited elastic modulus range of hydrogels while maintaining their biocompatibility benefits
4Object-affected harmful factors
If mechanotransduction inhibitors are administered, then inflammation and fibrosis are reduced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent applies preliminary action by incorporating mechanotransduction-inhibiting surface characteristics (controlled roughness and hydroxyapatite composition) directly into the implant before implantation. This preliminary modification of the implant surface creates a mechanically optimized interface that proactively reduces inflammation and fibrosis from the outset, eliminating the need for post-implantation pharmacological interventions and thereby reducing treatment protocol complexity
Data Source
AI summary
The present invention relates to the prevention and treatment of implant associated complications; e.g. foreign body response (FBR). High mechanical stress at the implant-tissue interface activates a sustained inflammatory response, which is primarily responsible for implant associated complications and implant failure. In particular, described herein are apparatuses, devices, and compositions containing inhibitors of mechanotransduction, and methods of making and using such apparatuses, devices and compositions. These apparatuses, devices, compositions, and methods are useful for preventing or reducing unwanted fibrosis, inflammation or cancer that result from implantation of a biomedical implant in an individual. One aspect of the invention provides a biomedical device including an effective amount of a composition containing a mechanotransduction inhibitor for preventing, inhibiting or treating implant associated complications.